Lack of oral embryotoxicity/teratogenicity with D-ribose in Wistar rats.
The present oral embryotoxicity/teratogenicity study of d-Ribose (DR) was conducted in female rats; 28 rats/group were exposed via the diet to 0, 5, 10, or 20% DR (0.0, 4.25, 7.94, 9.91g/kg body weight/day), from day 0 of gestation until Caesarian section and maternal sacrifice on day 21. All animals survived to the end of the study. Fecundity index, gestation index, pre-implantation loss, post-implantation loss, and sex ratio were all unaffected by treatment with DR. External observations of fetuses and placentas were unremarkable across the study groups. Mean fetal and placental weights, across all viable fetuses, did not differ significantly between treated and control groups. Observations of visceral malformations, anomalies, and variations were unremarkable and did not differ between treated and control groups. In summary, administration of DR to pregnant rats at concentrations up to 20% of the diet resulted in no significant adverse effects on the developing embryo/fetus at doses that were not otherwise a severe metabolic stress on the dam. A No Observed Adverse Effect Level (NOAEL) for teratogenicity could be seen at a concentration of 5% DR in the diet, corresponding to an average daily intake of DR of between 3.64 and 4.61g/kg body weight/day.
Griffiths
James C
JC
Burdock Group, Vero Beach, FL 32960, USA. jgriffiths@burdockgroup.com
Borzelleca
Joseph F
JF
St Cyr
John
J
D000818:Animals; D002432:Cecum / Q000187:drug effects / Q000473:pathology; D003257:Consumer Product Safety; D019587:Dietary Supplements / Q000633:toxicity*; D005260:Female; D005333:Fetus / Q000187:drug effects*; D007441:Intubation, Gastrointestinal; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D018811:Maternal Exposure; D011247:Pregnancy; D051381:Rats; D017208:Rats, Wistar; D012266:Ribose / Q000008:administration & dosage / Q000633:toxicity*; D018675:Toxicity Tests
D012266:Ribose